We believe our products have the potential to impact people's lives. That's why we're thrilled to present our unique offerings.
See approved products below.
endocrinology
| Product logo | Product name | Description |
|---|---|---|
|
Gvoke HypoPen®
(glucagon injection)
|
Gvoke HypoPen® is the first FDA-approved autoinjector for very low blood sugar that is premixed and ready to go. It is a prescription medicine used to treat very low blood sugar (severe hypoglycemia) in adults and children ages 2 years and above with diabetes. It is available in both pediatric (0.5mg/0.1mL) and adult (1.0mg/0.2mL) doses. |
|
Ogluo®
(glucagon)
|
Ogluo®** (glucagon injection) received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in December 2020 and the European Commission (EC) granted the marketing authorization on 11 February 2021. The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) approved Ogluo on April 29, 2021. Ogluo is indicated for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. **Xeris has an exclusive agreement with Tetris Pharma Limited, a subsidiary of Arecor Therapeutics plc, for the commercialization of Ogluo® in the European Economic Area, United Kingdom, and Switzerland. |
|
Recorlev®
(levoketoconazole)
|
Recorlev® is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. |
neurology
| Product logo | Product name | Description |
|---|---|---|
|
Keveyis®
(dichlorphenamide)
|
KEVEYIS® is the first FDA-approved treatment for Primary Periodic Paralysis. It is a prescription drug used to treat primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and other similar diseases. Keveyis has been shown to reduce the number, severity, and duration of Primary Periodic Paralysis attacks. |